Associated Papers
Pan-cancer analysis of ALK mutation and its association with tumor immunogenicity and the efficacy of immune checkpoint blockade.
Huang Z et al.
Genes & Diseases, 2026
A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors.
Oh HC et al.
Genome Biology, 2026
Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.
Ai X et al.
European Journal of Cancer (oxford, England : 1990), 2026
Sustained Complete Response to Brigatinib in a Young Patient With ALK-Positive NSCLC Harboring I1171N Mutation Post-Alectinib Resistance.
Kapoor A et al.
Case Reports in Oncological Medicine, 2026
Clinical Outcomes of Patients With Advanced ALK-Rearranged Lung Squamous Cell Carcinoma Treated With ALK Tyrosine Kinase Inhibitors.
Sun Y et al.
Clinical Lung Cancer, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Discovery of an ALK degrader for lorlatinib-resistant compound mutations.
Gao F et al.
European Journal of Medicinal Chemistry, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Spectrum of Resistance Mechanisms to ALK TKIs in NSCLC: Largest Single-Center Experience from India.
Batra U et al.
South Asian Journal of Cancer, 2025
MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.
Hu J et al.
Molecular Oncology, 2025
Prediction of potential drug-resistant ALK mutations against fourth-generation inhibitors NVL-655 and TPX-0131.
Zhao F et al.
International Journal of Biological Macromolecules, 2025
ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion.
Choi S et al.
Cancer Research and Treatment, 2025
Iruplinalkib for G1202R-mutant non-small cell lung cancer with anaplastic lymphoma kinase double fusion failed to alectinib: a case report.
Yang G et al.
Anti-cancer Drugs, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Discovery and preclinical evaluations of drug candidate DA-0157 capable of overcoming EGFR drug-resistant mutation C797S and EGFR/ALK co-mutations.
He P et al.
European Journal of Medicinal Chemistry, 2025
Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC.
Nousias O et al.
Lung Cancer (amsterdam, Netherlands), 2025
Exceptional response to brigatinib following alectinib failure in a patient with ALK fusion-positive duodenal carcinoma.
Sasaki A et al.
International Cancer Conference Journal, 2025
Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients.
Li W et al.
Cancers, 2025
A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung Cancer.
Chan SWS et al.
Clinical Lung Cancer, 2025
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer.
Zapata Dongo RJ et al.
Frontiers in Pharmacology, 2025
Case Report: Treatment response of SQSTM1-ALK fusion lung adenocarcinoma to multiple ALK inhibitors.
Gu J et al.
Frontiers in Pharmacology, 2025
OKAIN: A comprehensive oncology knowledge base for the interpretation of clinically actionable alterations.
Yang Z et al.
Open Medicine (warsaw, Poland), 2025
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Lin JJ et al.
Cancer Discovery, 2024
Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients.
Jha P et al.
Clinical Lung Cancer, 2024
In-depth theoretical modeling to explore the mechanism of TPX-0131 overcoming lorlatinib resistance to ALKL1196M/G1202R mutation.
Zhang X et al.
Computers in Biology and Medicine, 2024
A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review.
Wang Z et al.
Discover Oncology, 2024
An Inflammatory Myofibroblastic Tumor With a Novel ALKV1180L Mutation Leading to Acquired Resistance to Tyrosine Kinase Inhibitors.
Sharpe B et al.
Genes, Chromosomes & Cancer, 2024
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.
Vasseur D et al.
Molecular Cancer, 2024
Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors.
Hickman RA et al.
Acta Neuropathologica Communications, 2024
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.
Ek T et al.
Cancer Research Communications, 2024
ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance.
Itchins M et al.
Jto Clinical and Research Reports, 2024
Understanding variants of unknown significance and classification of genomic alterations.
Pavlick DC et al.
The Oncologist, 2024
Metastatic Non-Myofibroblastic Sarcoma Harbouring EML4-ALK Fusion-Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations.
Wilson I et al.
Cancer Reports (hoboken, N.j.), 2024
Analysis of the resistance profile of real-world alectinib first-line therapy in patients with ALK rearrangement-positive advanced non-small cell lung cancer using organoid technology in one case of lung cancer.
Xie Y et al.
Journal of Thoracic Disease, 2024
Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report.
He Q et al.
Heliyon, 2024
Pathway-based, reaction-specific annotation of disease variants for elucidation of molecular phenotypes.
Orlic-Milacic M et al.
Database : the Journal of Biological Databases and Curation, 2024
UNG-RPA interaction governs the choice between high-fidelity and mutagenic uracil repair.
Mu Y et al.
Biorxiv : the Preprint Server for Biology, 2024
Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome.
Diaz-Jimenez A et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2024
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Zheng J et al.
Cancer Communications (london, England), 2024
HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors.
Kim M et al.
Translational Lung Cancer Research, 2024
Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.
Zhang X et al.
Computers in Biology and Medicine, 2024
A novel secondary ALK gene mutation which resistant to second-generation TKIs: a case report and literature review.
Cheng X et al.
Frontiers in Oncology, 2024
Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy.
Sasaki T et al.
Translational Lung Cancer Research, 2023
Impact of compound mutations I1171N + F1174I and I1171N + L1198H on the structure of ALK in NSCLC pathogenesis: atomistic insights.
Salifu EY et al.
Journal of Biomolecular Structure & Dynamics, 2023